Moriah P. Bellissimo
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Moriah P. Bellissimo has a total of 105 co-authors. Here are the top co-authors by number of shared publications:
Glenn J. Lesser
Department of Cancer Medicine, Wake Forest University School of Medicine, Winston-Salem, North Carolina, USA
7 shared publications- William Gregory Hundley
Department of Internal Medicine, Division of Cardiology, Pauley Heart Center, Virginia Commonwealth University School of Medicine, Richmond, USA
7 shared publications Bonnie Ky
Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania, USA
6 shared publicationsThomas R. Ziegler
Division of Endocrinology, Lipids and Metabolism, Department of Medicine Emory University School of Medicine Atlanta Georgia USA
6 shared publicationsKerryn W. Reding
Affiliation Department of Biobehavioral Nursing and Health Informatics, University of Washington School of Nursing, Seattle, Washington, United States of America
5 shared publicationsDean P. Jones
Emory Univ, Sch Med, Dept Med, Div Pulm Allergy Crit Care & Sleep Med, Atlanta, GA USA
4 shared publications
Latest Publications
- Open Access
- 21 April 2026
- Published by Elsevier in JACC: Cardiooncology
- Vol. 8 (2) , 192-194
Elevated Plasma IL-18 Levels During Chemotherapy Treatment for Breast Cancer, Exercise Capacity, and Physical Activity
- 21 April 2026
- Published by Elsevier in JACC: Cardiooncology
- Vol. 8 (2) , 192-194
Open AccessElevated Plasma IL-18 Levels During Chemotherapy Treatment for Breast Cancer, Exercise Capacity, and Physical Activity
- Open Access
- 12 February 2026
- Published by Springer Nature in Quality of Life Research
- Vol. 35 (3) , 71
Muscle quality during cancer treatment and associations with health-related quality of life
Purpose: Breast cancer (BC) survivors report declines in health-related quality of life (HRQoL), including worsening physical function and fatigue levels. It is uncertain if these changes are associated with muscle quality. This study estimated changes in muscle quality and HRQoL in BC participants over 24 months of treatment and tested associations with muscle quality and HRQoL. Methods: Women (n = 149, 50.3 ± 10.7 years) diagnosed with stage I-III BC (PREVENT-WF-98213) reported HRQoL via Patient-Reported Outcomes Measurement Information System (PROMIS) surveys at baseline prior to cancer treatment and at 6-months and 24-months follow up from treatment initiation. Paraspinal intermuscular fat (IMF) and skeletal muscle (SM) were determined by magnetic resonance imaging, and the IMF:SM ratio was calculated to estimate muscle quality. Analyses included linear mixed-effects models adjusting for study group (placebo/statin), age, race, and body mass index. Results: HRQoL declined from baseline to 6-months but returned to baseline levels by 24-months. Muscle quality worsened from baseline through 24-months manifested by an increase in IMF. Individuals with better muscle quality at baseline reported declines in HRQoL from baseline to 6-months (mean difference [MD] = − 0.12 ± 0.03, p < 0.001), whereas participants with poor baseline muscle quality did not (MD = − 0.06 ± 0.003, p = 0.14). An increase in IMF:SM over 24-months trended towards worse physical function (− 8.76 ± 5.79, p = 0.132). Conclusion: Muscle quality worsened over 24-months and trended toward worse physical function at 24-months follow-up. From initial declines during treatment, participants reported recovered HRQoL by 24-months. Further work in a larger cohort is needed to confirm associations with muscle quality and physical function.
- 12 February 2026
- Published by Springer Nature in Quality of Life Research
- Vol. 35 (3) , 71
Open AccessMuscle quality during cancer treatment and associations with health-related quality of life
Purpose: Breast cancer (BC) survivors report declines in health-related quality of life (HRQoL), including worsening physical function and fatigue levels. It is uncertain if these changes are associated with muscle quality. This study estimated changes in muscle quality and HRQoL in BC participants over 24 months of treatment and tested associations with muscle quality and HRQoL. Methods: Women (n = 149, 50.3 ± 10.7 years) diagnosed with stage I-III BC (PREVENT-WF-98213) reported HRQoL via Patient-Reported Outcomes Measurement Information System (PROMIS) surveys at baseline prior to cancer treatment and at 6-months and 24-months follow up from treatment initiation. Paraspinal intermuscular fat (IMF) and skeletal muscle (SM) were determined by magnetic resonance imaging, and the IMF:SM ratio was calculated to estimate muscle quality. Analyses included linear mixed-effects models adjusting for study group (placebo/statin), age, race, and body mass index. Results: HRQoL declined from baseline to 6-months but returned to baseline levels by 24-months. Muscle quality worsened from baseline through 24-months manifested by an increase in IMF. Individuals with better muscle quality at baseline reported declines in HRQoL from baseline to 6-months (mean difference [MD] = − 0.12 ± 0.03, p < 0.001), whereas participants with poor baseline muscle quality did not (MD = − 0.06 ± 0.003, p = 0.14). An increase in IMF:SM over 24-months trended towards worse physical function (− 8.76 ± 5.79, p = 0.132). Conclusion: Muscle quality worsened over 24-months and trended toward worse physical function at 24-months follow-up. From initial declines during treatment, participants reported recovered HRQoL by 24-months. Further work in a larger cohort is needed to confirm associations with muscle quality and physical function.
- Open Access
- 15 January 2026
- Published by Wiley in Nutrition in Clinical Practice
- Vol. 41 (3) , 849-858
Interrelationships among handgrip strength, body composition, physical activity, and quality of life in adults with cystic fibrosis: A cross‐sectional study
Background: In individuals with cystic fibrosis (CF), lean mass and muscle strength are important predictors of clinical outcomes. This study evaluated associations among body composition, handgrip strength, muscle quality, physical activity, and health‐related quality of life in CF. Methods: This observational, cross‐sectional study included 27 adults with CF and 24 age‐matched healthy controls. Body composition was assessed using dual‐energy x‐ray absorptiometry, physical activity by self‐reported questionnaire, strength by handgrip dynamometry, and quality of life by the CF Quality of Life‐Revised (CFQ‐R) questionnaire. Muscle quality was defined as handgrip strength divided by appendicular lean mass. Analyses included t ‐ tests and Pearson or Spearman correlations. Results: Demographics, body composition, handgrip strength, and muscle quality were similar between those with CF and controls. Among those with CF, muscle quality was positively associated with total physical activity score ( r = 0.49, P = 0.009). Handgrip strength was positively associated with lean mass ( r = 0.86, P < 0.001) and bone mineral density ( r = 0.64, P < 0.001). Regarding CFQ‐R, lean mass was positively associated with body image and emotion ( r = 0.41, P = 0.03), and body fat was associated with lower physical functioning ( r = −0.63, P = 0.004), greater treatment burdens ( r = −0.49, P = 0.01), and worse digestive health ( r = −0.45, P = 0.02). Conclusion: As the CF population ages, these data support continued efforts to promote physical activity and improve body composition for enhanced quality of life while also highlighting the value of integrating accessible measures of muscle function and quality into routine clinical care.
- 15 January 2026
- Published by Wiley in Nutrition in Clinical Practice
- Vol. 41 (3) , 849-858
Open AccessInterrelationships among handgrip strength, body composition, physical activity, and quality of life in adults with cystic fibrosis: A cross‐sectional study
Background: In individuals with cystic fibrosis (CF), lean mass and muscle strength are important predictors of clinical outcomes. This study evaluated associations among body composition, handgrip strength, muscle quality, physical activity, and health‐related quality of life in CF. Methods: This observational, cross‐sectional study included 27 adults with CF and 24 age‐matched healthy controls. Body composition was assessed using dual‐energy x‐ray absorptiometry, physical activity by self‐reported questionnaire, strength by handgrip dynamometry, and quality of life by the CF Quality of Life‐Revised (CFQ‐R) questionnaire. Muscle quality was defined as handgrip strength divided by appendicular lean mass. Analyses included t ‐ tests and Pearson or Spearman correlations. Results: Demographics, body composition, handgrip strength, and muscle quality were similar between those with CF and controls. Among those with CF, muscle quality was positively associated with total physical activity score ( r = 0.49, P = 0.009). Handgrip strength was positively associated with lean mass ( r = 0.86, P < 0.001) and bone mineral density ( r = 0.64, P < 0.001). Regarding CFQ‐R, lean mass was positively associated with body image and emotion ( r = 0.41, P = 0.03), and body fat was associated with lower physical functioning ( r = −0.63, P = 0.004), greater treatment burdens ( r = −0.49, P = 0.01), and worse digestive health ( r = −0.45, P = 0.02). Conclusion: As the CF population ages, these data support continued efforts to promote physical activity and improve body composition for enhanced quality of life while also highlighting the value of integrating accessible measures of muscle function and quality into routine clinical care.
- Open Access
- 16 September 2025
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 20 (9) , e0318017
Statins to reduce renal sinus fat among breast cancer patients undergoing anthracycline-based chemotherapy: A substudy of PREVENT-WF-98213
Objective: To test if statin administration attenuated renal sinus fat (RSF) accumulation and if RSF was associated with renal function in women with breast cancer (BC) receiving anthracycline-based chemotherapy. Methods: This was a secondary analysis in a subgroup of women with stage I-III BC randomized to placebo (n = 35) or statin (40 mg/day atorvastatin, n = 44) therapy. At baseline and 24-months after randomization, RSF and intraabdominal fat were measured from magnetic resonance images, and estimated glomerular filtration rate (eGFR) was calculated from serum creatinine. Results: Participants in this study averaged 51 years of age (SD 11), 87% reported White race, and had a mean BMI (±SD) of 30.2 kg/m2 (±6.1). Most participants (60%) were diagnosed with stage II BC. At 24-months, RSF was higher in the placebo group relative to the statin group (β [95% CI], p-value: 0.17 [0.009, 0.34], p = 0.04). After adjusting for baseline RSF, this signal remained but was attenuated (β [95% CI], p-value: 0.12 [−0.06, 0.29], p = 0.18). In all participants at baseline and prior to beginning chemotherapy for BC or study drug, higher RSF was associated with lower eGFR values in all participants (r = −0.23, p = 0.03). At 24-months by study group, greater RSF was associated with decreased eGFR in the placebo group (−0.51, p = 0.01) but not in the statin group (−0.25, p = 0.19). Discussion: Statin administration may lower RSF during anthracycline-based chemotherapy. These findings merit further investigation to determine if statins protect renal function during BC treatment.
- 16 September 2025
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 20 (9) , e0318017
Open AccessStatins to reduce renal sinus fat among breast cancer patients undergoing anthracycline-based chemotherapy: A substudy of PREVENT-WF-98213
Objective: To test if statin administration attenuated renal sinus fat (RSF) accumulation and if RSF was associated with renal function in women with breast cancer (BC) receiving anthracycline-based chemotherapy. Methods: This was a secondary analysis in a subgroup of women with stage I-III BC randomized to placebo (n = 35) or statin (40 mg/day atorvastatin, n = 44) therapy. At baseline and 24-months after randomization, RSF and intraabdominal fat were measured from magnetic resonance images, and estimated glomerular filtration rate (eGFR) was calculated from serum creatinine. Results: Participants in this study averaged 51 years of age (SD 11), 87% reported White race, and had a mean BMI (±SD) of 30.2 kg/m2 (±6.1). Most participants (60%) were diagnosed with stage II BC. At 24-months, RSF was higher in the placebo group relative to the statin group (β [95% CI], p-value: 0.17 [0.009, 0.34], p = 0.04). After adjusting for baseline RSF, this signal remained but was attenuated (β [95% CI], p-value: 0.12 [−0.06, 0.29], p = 0.18). In all participants at baseline and prior to beginning chemotherapy for BC or study drug, higher RSF was associated with lower eGFR values in all participants (r = −0.23, p = 0.03). At 24-months by study group, greater RSF was associated with decreased eGFR in the placebo group (−0.51, p = 0.01) but not in the statin group (−0.25, p = 0.19). Discussion: Statin administration may lower RSF during anthracycline-based chemotherapy. These findings merit further investigation to determine if statins protect renal function during BC treatment.
- Open Access
- 25 February 2025
- Published by Elsevier in JACC: Cardiooncology
- Vol. 7 (3) , 297-299
Intermuscular Fat and Physical Activity Levels Relative to Exercise Capacity Change During Breast Cancer Treatment
- 25 February 2025
- Published by Elsevier in JACC: Cardiooncology
- Vol. 7 (3) , 297-299
Open AccessIntermuscular Fat and Physical Activity Levels Relative to Exercise Capacity Change During Breast Cancer Treatment
- Open Access
- 18 June 2024
- Published by Elsevier in JACC: Cardiooncology
- Vol. 6 (3) , 467-469
Black-White Disparities in Submaximal Exercise Capacity Reductions in Breast Cancer Survivors
- 18 June 2024
- Published by Elsevier in JACC: Cardiooncology
- Vol. 6 (3) , 467-469
Open AccessBlack-White Disparities in Submaximal Exercise Capacity Reductions in Breast Cancer Survivors
- Open Access
- 15 May 2024
- Published by Elsevier in JACC: Advances
- Vol. 3 (6)
Low-Carbohydrate High-Fat Diets, Lipid Levels, and Cardiovascular Risk
- 15 May 2024
- Published by Elsevier in JACC: Advances
- Vol. 3 (6)
Open AccessLow-Carbohydrate High-Fat Diets, Lipid Levels, and Cardiovascular Risk
- 17 October 2023
- Published by Elsevier in Progress in Cardiovascular Diseases
- Vol. 81, 10-16
Higher diet quality relates to better cardiac function in cancer survivors: The multi-ethnic study of atherosclerosis
- 17 October 2023
- Published by Elsevier in Progress in Cardiovascular Diseases
- Vol. 81, 10-16
Higher diet quality relates to better cardiac function in cancer survivors: The multi-ethnic study of atherosclerosis
- Open Access
- 21 March 2023
- Published by Elsevier in JACC: Cardiooncology
- Vol. 5 (5) , 641-652
Physical Activity During Breast Cancer Therapy Associates With Preserved Exercise Capacity and Cardiac Function (WF97415)
- 21 March 2023
- Published by Elsevier in JACC: Cardiooncology
- Vol. 5 (5) , 641-652
Open AccessPhysical Activity During Breast Cancer Therapy Associates With Preserved Exercise Capacity and Cardiac Function (WF97415)